Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Zimran

Showing results (131-140 of 135) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 135 results.
Blood Cells, Molecules & Diseases|December 4, 2012
Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher diseaseL van Dussen, A Zimran, E M Akkerman, et al.
Journal of Inherited Metabolic Disease|October 27, 2004
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher diseaseD Elstein, C Hollak, J M F G Aerts, et al.
Journal of Inherited Metabolic Disease|June 19, 2001
Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapyF M Platt, M Jeyakumar, U Andersson, et al.
Journal of Inherited Metabolic Disease|November 8, 2003
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statementT M Cox, J M F G Aerts, G Andria, et al.
Blood Cells, Molecules & Diseases|March 10, 2017
Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher diseaseM Biegstraaten, T M Cox, N Belmatoug, et al.
Pageof 14

Showing results (131-140 of 135) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 135 results.
Blood Cells, Molecules & Diseases|December 4, 2012
Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher diseaseL van Dussen, A Zimran, E M Akkerman, et al.
Journal of Inherited Metabolic Disease|October 27, 2004
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher diseaseD Elstein, C Hollak, J M F G Aerts, et al.
Journal of Inherited Metabolic Disease|June 19, 2001
Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapyF M Platt, M Jeyakumar, U Andersson, et al.
Journal of Inherited Metabolic Disease|November 8, 2003
The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statementT M Cox, J M F G Aerts, G Andria, et al.
Blood Cells, Molecules & Diseases|March 10, 2017
Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher diseaseM Biegstraaten, T M Cox, N Belmatoug, et al.
Pageof 14